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Background: Clinical trials have demonstrated that lifestyle modification and metformin can delay or prevent progression of prediabetic states 
(impaired fasting glucose (IFG) and impaired glucose tolerance (IGT)), to type 2 diabetes mellitus, while reducing cardiovascular complications. Our 
objective is to estimate rates of prevalence, diagnosis, and treatment of IFG and IGT.
Methods: A representative sample of the US population (the 2005-2006 National Health And Nutrition Examination Survey including 1,547 
nondiabetic adults (age >18) without a history of myocardial infarction) was assessed to determine the proportion of adults who met criteria for 
IFG/IGT, and the proportion of IFG/IGT subjects who: 1) reported receiving a diagnosis from their physician; 2) were prescribed lifestyle modification 
or an antihyperglycemic agent; and 3) were currently on therapy. We used multivariable regression analysis to identify predictors of diagnosis and 
treatment.
Results: Of the 1,547 subjects age >18 without a history of myocardial infarction, 34.6% (CI 30-39%) were dysglycemic: 19.5% had IFG only, 5.9% 
had IGT only, and 9.2% had both. The mean Framingham 10-year risk of cardiovascular events was 6.9 ± 8.0% for dysglycemic patients, versus 2.8 
± 5.8 % in normoglycemic patients (p<0.001). Only 4.8% of dysglycemic subjects reported having received a formal diagnosis from their physicians. 
No dysglycemic patients received oral antihyperglycemics, and rates of recommendation for exercise or diet were 33.4% and 31.7%, respectively. 
Among the 47.7% dysglycemic patients who exercised, 54.6% reported exercising for at least 30 minutes daily.
Conclusions: Three years after clinical trials demonstrated the benefits of preventing diabetes in IFG/IGT patients, the majority of IFG/IGT patients 
were undiagnosed and untreated with guideline based interventions that can arrest progression to type 2 diabetes mellitus while reducing risks of 
cardiovascular complications. 
